Sign In
Buy SLRX
$0.84
+0 (+0%)
At Close: Apr 14, 2026
Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 20.9%
03:20am, Wednesday, 21'st Jan 2026
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 223,
Trading under DCOY to commence on January 8, 2026 Company's proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient
Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Down 2.6% – Should You Sell?
01:51am, Tuesday, 30'th Dec 2025
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX - Get Free Report)'s stock price fell 2.6% during mid-day trading on Monday. The stock traded as low as $0.62 and last traded at $0.64. 196,853 shares chan
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
11:12am, Friday, 19'th Dec 2025
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annu
Comparing NRx Pharmaceuticals (NASDAQ:NRXP) & Salarius Pharmaceuticals (NASDAQ:SLRX)
01:42am, Friday, 19'th Dec 2025
Salarius Pharmaceuticals (NASDAQ: SLRX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead a
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
08:00am, Monday, 01'st Dec 2025
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP 3 ACT™ platform, show excellent in silico free energy binding to the viral target entry protei
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
08:45am, Thursday, 13'th Nov 2025
Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined company h
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
09:18am, Tuesday, 11'th Nov 2025
HOUSTON , Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
08:45am, Monday, 13'th Oct 2025
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:00am, Tuesday, 09'th Sep 2025
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasda
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
08:30am, Thursday, 14'th Aug 2025
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
08:30am, Monday, 14'th Jul 2025
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Sto
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Ther
